Enanta Pharmaceuticals, Inc. v. Pfizer Inc., No. 25-1427 (Fed. Cir. June 23, 2026)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Enanta Pharmaceuticals, Inc. (“Enanta”) appeals from a decision of the United States District Court for the Dis- trict of Massachusetts granting summary judgment that all claims of Enanta’s U.S. Patent 11,358,953 (“the ’953 pa- tent”) are invalid as anticipated by a public disclosure of a compound within the scope of its claims. Enanta Pharms., Inc. v. Pfizer, Inc. , No. 22-cv-10967-DJC, 2024 WL 5203036, at *9 (D. Mass. Dec. 23, 2024) (“Decision”).1 For the following reasons, we affirm.